CN107787227A - Nut中线癌的治疗 - Google Patents
Nut中线癌的治疗 Download PDFInfo
- Publication number
- CN107787227A CN107787227A CN201680036201.4A CN201680036201A CN107787227A CN 107787227 A CN107787227 A CN 107787227A CN 201680036201 A CN201680036201 A CN 201680036201A CN 107787227 A CN107787227 A CN 107787227A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- alkylene
- cycloalkyl
- heterocycloalkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(CC(*[N+]1/C(/C)=*/N)N=C(CCC/C(/Cl)=C\**)c2c1[s]c(C)c2C)OC(C)(C)C Chemical compound CC(CC(*[N+]1/C(/C)=*/N)N=C(CCC/C(/Cl)=C\**)c2c1[s]c(C)c2C)OC(C)(C)C 0.000 description 7
- DZWZNSVWNHAIFT-UHFFFAOYSA-P CC(C)C1(c(cc2)ccc2Cl)[NH2+]C(CC(OC(C)(C)C)=O)c2[nH+]cc(C)[n]2-c2c1c(C)c(C)[s]2 Chemical compound CC(C)C1(c(cc2)ccc2Cl)[NH2+]C(CC(OC(C)(C)C)=O)c2[nH+]cc(C)[n]2-c2c1c(C)c(C)[s]2 DZWZNSVWNHAIFT-UHFFFAOYSA-P 0.000 description 1
- ZMMSINKSIVFYMS-UHFFFAOYSA-P CC(CC(OC(C)(C)C)=[OH+])C1=[NH+][NH+2]C(C)(C(F)([FH+])[FH+])N1c1c(C(c(cc2)ccc2Cl)=[NH2+])c(C)c(C)[s]1 Chemical compound CC(CC(OC(C)(C)C)=[OH+])C1=[NH+][NH+2]C(C)(C(F)([FH+])[FH+])N1c1c(C(c(cc2)ccc2Cl)=[NH2+])c(C)c(C)[s]1 ZMMSINKSIVFYMS-UHFFFAOYSA-P 0.000 description 1
- WWAITXANBSTWLY-UHFFFAOYSA-P CC1Nc([sH+]c(C)c2C)c2C(c(cc2)ccc2Cl)=NC1CC([NH2+]CCN1CCN(C)CC1)=O Chemical compound CC1Nc([sH+]c(C)c2C)c2C(c(cc2)ccc2Cl)=NC1CC([NH2+]CCN1CCN(C)CC1)=O WWAITXANBSTWLY-UHFFFAOYSA-P 0.000 description 1
- RMTWKGJNUSKTTA-HEPHUNMXSA-N C[IH]C(N/N=C/C(NC/C=C/N)=C)=O Chemical compound C[IH]C(N/N=C/C(NC/C=C/N)=C)=O RMTWKGJNUSKTTA-HEPHUNMXSA-N 0.000 description 1
- IWHKUHARIIUFSS-UHFFFAOYSA-N Cc1c(C)[s]c-2c1C(c(cc1)ccc1Br)=NCc1nnc(C)[n]-21 Chemical compound Cc1c(C)[s]c-2c1C(c(cc1)ccc1Br)=NCc1nnc(C)[n]-21 IWHKUHARIIUFSS-UHFFFAOYSA-N 0.000 description 1
- KVLMRYBNORJPIO-UHFFFAOYSA-N Cc1c(C)[s]c-2c1C(c(cc1)ccc1Cl)=NCc1nnc(C)[n]-21 Chemical compound Cc1c(C)[s]c-2c1C(c(cc1)ccc1Cl)=NCc1nnc(C)[n]-21 KVLMRYBNORJPIO-UHFFFAOYSA-N 0.000 description 1
- RKKYJPCAEJXOSC-UHFFFAOYSA-N Cc1c[s]c-2c1C(c1ccc(C)cc1)=NC(CC(NCCc1cnccc1)O)c1nnc(C)[n]-21 Chemical compound Cc1c[s]c-2c1C(c1ccc(C)cc1)=NC(CC(NCCc1cnccc1)O)c1nnc(C)[n]-21 RKKYJPCAEJXOSC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- G01N2333/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185203P | 2015-06-26 | 2015-06-26 | |
| US62/185,203 | 2015-06-26 | ||
| PCT/US2016/039270 WO2016210275A1 (en) | 2015-06-26 | 2016-06-24 | Treatment of nut midline carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107787227A true CN107787227A (zh) | 2018-03-09 |
Family
ID=56409188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680036201.4A Pending CN107787227A (zh) | 2015-06-26 | 2016-06-24 | Nut中线癌的治疗 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180193350A1 (https=) |
| EP (1) | EP3314005A1 (https=) |
| JP (1) | JP2018520124A (https=) |
| KR (1) | KR20180035785A (https=) |
| CN (1) | CN107787227A (https=) |
| AR (1) | AR105124A1 (https=) |
| AU (1) | AU2016283020A1 (https=) |
| BR (1) | BR112017028178A2 (https=) |
| CA (1) | CA2989313A1 (https=) |
| HK (1) | HK1252062A1 (https=) |
| IL (1) | IL256186A (https=) |
| MA (1) | MA42249A (https=) |
| MX (1) | MX2017016337A (https=) |
| WO (1) | WO2016210275A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2902030T3 (pl) | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| CA2929652A1 (en) | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| SG11201607108XA (en) | 2014-02-28 | 2016-09-29 | Tensha Therapeutics Inc | Treatment of conditions associated with hyperinsulinaemia |
| BR112017008714A2 (pt) | 2014-10-27 | 2017-12-19 | Tensha Therapeutics Inc | inibidores de bromodomínio |
| EP4629984A1 (en) * | 2022-12-06 | 2025-10-15 | BioVentures, LLC | Development of potent dual hdac/brd4 inhibitors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103037865A (zh) * | 2010-05-14 | 2013-04-10 | 达那-法伯癌症研究所 | 用于治疗瘤形成、炎性疾病和其他失调的组合物和方法 |
| US20130261109A1 (en) * | 2007-12-28 | 2013-10-03 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| ES2563057T3 (es) | 2009-11-05 | 2016-03-10 | Glaxosmithkline Llc | Inhibidor de bromodominio de benzodiazepina |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| RS54645B1 (sr) | 2009-11-05 | 2016-08-31 | Glaxosmithkline Llc | Benzodiazepin kao inhibitor bromodomena |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| US9085582B2 (en) | 2010-06-22 | 2015-07-21 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2012151512A2 (en) | 2011-05-04 | 2012-11-08 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| EP2721031B1 (en) | 2011-06-17 | 2016-01-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| TWI602820B (zh) | 2012-06-06 | 2017-10-21 | 星宿藥物公司 | 溴域抑制劑及其用途 |
| SG11201607108XA (en) | 2014-02-28 | 2016-09-29 | Tensha Therapeutics Inc | Treatment of conditions associated with hyperinsulinaemia |
-
2016
- 2016-06-24 CA CA2989313A patent/CA2989313A1/en not_active Abandoned
- 2016-06-24 JP JP2017563973A patent/JP2018520124A/ja active Pending
- 2016-06-24 BR BR112017028178-3A patent/BR112017028178A2/en not_active Application Discontinuation
- 2016-06-24 AU AU2016283020A patent/AU2016283020A1/en not_active Abandoned
- 2016-06-24 MX MX2017016337A patent/MX2017016337A/es unknown
- 2016-06-24 AR ARP160101908A patent/AR105124A1/es unknown
- 2016-06-24 US US15/739,905 patent/US20180193350A1/en not_active Abandoned
- 2016-06-24 MA MA042249A patent/MA42249A/fr unknown
- 2016-06-24 EP EP16738292.8A patent/EP3314005A1/en not_active Withdrawn
- 2016-06-24 KR KR1020187000569A patent/KR20180035785A/ko not_active Withdrawn
- 2016-06-24 WO PCT/US2016/039270 patent/WO2016210275A1/en not_active Ceased
- 2016-06-24 CN CN201680036201.4A patent/CN107787227A/zh active Pending
- 2016-06-24 HK HK18111394.9A patent/HK1252062A1/zh unknown
-
2017
- 2017-12-07 IL IL256186A patent/IL256186A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130261109A1 (en) * | 2007-12-28 | 2013-10-03 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
| CN103037865A (zh) * | 2010-05-14 | 2013-04-10 | 达那-法伯癌症研究所 | 用于治疗瘤形成、炎性疾病和其他失调的组合物和方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3314005A1 (en) | 2018-05-02 |
| HK1252062A1 (zh) | 2019-05-10 |
| IL256186A (en) | 2018-02-28 |
| US20180193350A1 (en) | 2018-07-12 |
| AU2016283020A1 (en) | 2018-01-04 |
| JP2018520124A (ja) | 2018-07-26 |
| BR112017028178A2 (en) | 2018-08-28 |
| MX2017016337A (es) | 2018-11-22 |
| AR105124A1 (es) | 2017-09-06 |
| KR20180035785A (ko) | 2018-04-06 |
| WO2016210275A1 (en) | 2016-12-29 |
| MA42249A (fr) | 2018-05-02 |
| CA2989313A1 (en) | 2016-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107787227A (zh) | Nut中线癌的治疗 | |
| EA038337B1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| EP3810145A1 (en) | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use | |
| US20240335455A1 (en) | Mitofusin activators and uses thereof | |
| ES2896735T3 (es) | Eflornitina para su uso en el tratamiento del astrocitoma anaplásico recurrente/refractario por temozolomida | |
| KR102514814B1 (ko) | 인돌린 유사체 및 이의 용도 | |
| Dong et al. | Structure–activity relationship of SPOP inhibitors against kidney cancer | |
| US11896589B2 (en) | Diazinyl amino acridines and medical uses thereof | |
| EP2136829A1 (en) | Kinase protein binding inhibitors | |
| WO2016040527A1 (en) | Metabolism probes for therapy and diagnosis | |
| WO2021228210A1 (zh) | 吡咯烷类化合物及其应用 | |
| AU2006247803B2 (en) | Methods for treating drug resistant cancer | |
| US20250170097A1 (en) | Cathepsin inhibitors and use thereof in a method for detecting and treating resistance to immunotherapy | |
| TW202333704A (zh) | 用於治療腫瘤的藥物組合及其應用 | |
| TW583000B (en) | X-type sPLA2 inhibitor as a cancer therapeutical agent | |
| JP7652791B2 (ja) | α－シヌクレインの凝集に関連する疾患の診断、治療および予防のための新規な化合物 | |
| US12384751B2 (en) | Allosteric activators of the ALPHA1A-adrenergic receptor | |
| JP2024031105A (ja) | 線維症治療又は予防薬 | |
| CN110872341B (zh) | 一种靶向fgfr1的拮抗短肽 | |
| US9611276B2 (en) | Imidazo bicyclic iminium compounds as antitumor agents | |
| EP4008330A1 (en) | Combined inhibition of amino acid transporters for inhibiting human plasmacytoid dendritic cell activity during autoimmunity | |
| US12152008B2 (en) | Cyclopentaimidazolones for the treatment of cancer | |
| US20250122193A1 (en) | Novel pyridocarbazolium compounds and medical uses thereof | |
| Buzrieda | Discovery of highly potent and selective phosphatidylinositol 3-kinase-δ inhibitors for the treatment of blood cancers and autoimmune diseases | |
| CA3166527A1 (en) | Compositions and methods for treating neurodegenerative, neurodevelopmental, myodegenerative, and lysosomal storage disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1252062 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180309 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1252062 Country of ref document: HK |